Sun Pharma ដែលមានមូលដ្ឋាននៅឥណ្ឌា ប្រមូលទិញឱសថការប្រគុំតន្ត្រីក្នុងតម្លៃ 576 លានដុល្លារ បូករួមនឹងចំណុចសំខាន់ៗ

• Sun Pharmaceutical Industries Limited, India’s top pharmaceutical company, has agreed to acquire Concert Pharmaceuticals Inc (ផ្សារហ៊ុន NASDAQ: CNCE) for an upfront payment of $8.00 per share, or $576 million in equity value.

• Concert stockholders will also receive a non-tradeable contingent value right (CVR) entitling holders to receive up to an additional $3.50 per share in cash, payable upon deuruxolitinib achieving certain net sales milestones within specified periods.

• Concert is a late-stage biotechnology company, with its lead product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for Alopecia Areata, an autoimmune dermatological disease characterized by patchy hair loss.

• Concert has completed the evaluation of the efficacy and safety of deuruxolitinib in adult patients with moderate to severe Alopecia Areata in its THRIVE-AA Phase 3 study, and two open-label, long-term extension studies are ongoing.

• Sun Pharma’s immediate focus would be to follow Concert’s plan to submit a marketing application to the FDA in 1H of 2023.

• The transaction is expected to be completed in the first quarter of 2023.

• Sun Pharma had net cash of $1.6 billion, and Concert had approximately $148.9 million in cash, cash equivalents & investments as of September 30, 2022.

• សកម្មភាពតម្លៃ: CNCE shares are up 19.27% at $8.23 during the premarket session on the last check Thursday.

កុំខកខានការជូនដំណឹងតាមពេលវេលាជាក់ស្តែងលើភាគហ៊ុនរបស់អ្នក – ចូលរួម ប្រូម៉ាណា ដោយ​ឥតគិតថ្លៃ! សាកល្បងឧបករណ៍ដែលនឹងជួយអ្នកឱ្យវិនិយោគកាន់តែឆ្លាតវៃ លឿនជាងមុន និងប្រសើរជាងមុន។.

© ២០២០ Benzinga.com ។ Benzinga មិនផ្តល់ដំបូន្មានវិនិយោគទេ។ រក្សា​រ​សិទ្ធ​គ្រប់យ៉ាង។